• Kyverna Therapeutics announced sustained one-year benefits from its pivotal miv-cel trial in stiff person syndrome, supporting its regulatory application.
• Results from 26 patients showed lasting improvements in mobility, disability and quality of life; nearly all remained off chronic immunotherapies.
• Treatment remained well tolerated, with no severe cytokine release syndrome or neurotoxicity; all serious treatment-related adverse events resolved.
• The full one-year findings will be presented today at MS Toronto 2026; earlier results presented at AAN 2026 met key endpoints.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kyverna Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610210715PRIMZONEFULLFEED9850354) on October 21, 2026, and is solely responsible for the information contained therein.